InfuSystem Holdings, Inc. filings document financial reporting, governance and material-event disclosures for a health care service provider focused on outpatient durable medical equipment services. Recent 8-K filings furnish earnings releases, conference-call announcements, investor presentations and Regulation FD disclosures tied to Patient Services and Device Solutions.
The company’s proxy materials cover board matters, shareholder voting, executive compensation and equity award disclosures. Other filings document accounting oversight, including changes in the independent registered public accounting firm, audits of consolidated financial statements and internal control over financial reporting.
InfuSystem Holdings, Inc. Executive VP and CFO Barry G. Steele reported buying 7,000 shares of common stock in an open-market purchase at a weighted average price of $8.707 per share. Following this transaction, he directly holds 96,590 common shares, including 1,590 shares recently acquired through the Company’s Employee Stock Purchase Plan.
InfuSystem Holdings reported Q1 2026 net revenue of $33.7 million, down 3% from $34.7 million a year earlier, but moved to net income of $1.0 million versus a $0.3 million loss. Gross margin improved to 58.4% from 55.2% as higher-margin Patient Services outpaced softer Device Solutions.
Patient Services revenue rose 6.4% to $22.1 million, driven by oncology and fast-growing wound care, while Device Solutions fell 16.9% to $11.6 million amid lower biomedical services and prior-year rental buyout effects. Operating income more than doubled to $1.6 million. Cash was $2.1 million with $20.0 million drawn on a $75.0 million revolver and $55.0 million of remaining availability. The company continued its share repurchase program, having bought back $11.8 million of stock cumulatively.
InfuSystem Holdings reported first quarter 2026 net revenues of $33.7 million, down 3% from $34.7 million a year earlier, mainly due to a restructured GE Healthcare biomedical services contract. On a pro-forma basis, revenue grew 1.7%.
Patient Services net revenue rose 6% to $22.1 million, driven by Oncology and rapidly expanding Wound Care, while Device Solutions fell 17% to $11.6 million. Net income was $1.0 million, or $0.05 per diluted share, compared with a net loss of $0.3 million, or $0.01 per diluted share, last year.
Adjusted EBITDA was $6.4 million with an 18.9% margin, roughly flat in dollars but higher as a percentage of revenue. Liquidity totaled $57.1 million as of March 31, 2026, and the company reaffirmed full-year 2026 guidance for 6%–8% pro-forma net revenue growth and Adjusted EBITDA margins in the mid to low 20% range.
InfuSystem Holdings, Inc. announced it will release its first quarter 2026 financial results on May 7, 2026, before the market opens. On the same day, the Company will host a conference call at 9:00 a.m. Eastern Time for investors and other interested parties.
Participants can join by phone or via a live webcast in the Investors section of InfuSystem’s website, with a telephone and online replay available through May 14, 2026.
InfuSystem Holdings, Inc. is asking shareholders to approve seven director nominees, an advisory vote on executive pay, an increase to its 2021 Equity Incentive Plan share pool, and ratification of Grant Thornton as auditor at a fully virtual May 11, 2026 annual meeting.
The proxy highlights a strong 2025, with record revenue of $143.4 million, up 6%, net income of $6.6 million, up 183%, and record Adjusted EBITDA of $31.5 million with a 21.9% margin. Operating cash flow rose to $24.4 million, while capital spending fell by more than 50%, net debt dropped 30% to $16.4 million, and the company repurchased 1.3 million shares for $9.9 million.
Management describes a shift toward less capital‑intensive growth, led by rapid expansion in wound care and continued oncology strength, and notes a 2026 restructuring of its largest biomedical services contract that will reduce annual revenue by $7.1 million but is expected to improve earnings and cash flow. The board seeks to add 1,000,000 shares to the 2021 Equity Incentive Plan, bringing the reserve to 7,000,000 shares, to continue using equity awards as a key part of executive and director compensation.
InfuSystem Holdings, Inc. has changed its independent auditor for the fiscal year ending December 31, 2026. After a competitive selection process, the board’s Audit Committee dismissed Deloitte & Touche LLP and appointed Grant Thornton LLP to audit the 2026 consolidated financial statements, quarterly reviews, and internal control over financial reporting.
The company states that Deloitte’s audit reports for 2025 and 2024 contained no adverse opinions, disclaimers, or qualifications. It also reports no disagreements or reportable events with Deloitte over those years and through March 13, 2026, and says it did not previously consult Grant Thornton on accounting or audit matters. A confirming letter from Deloitte is filed as an exhibit.
InfuSystem Holdings, Inc. reported that President and Chief Executive Officer Carrie Lachance and Chief Financial Officer Barry Steele will participate in the 38th Annual ROTH Conference on March 23, 2026, at The Ritz-Carlton Laguna Niguel in Dana Point, California.
Management plans to host in-person one-on-one meetings with investors throughout the day, arranged through ROTH Capital conference representatives or the event registration site. The company describes itself as a leading national health care service provider with two main platforms, Patient Services and Device Solutions, supporting outpatient care involving complex durable medical equipment.
InfuSystem Holdings executive Barry G. Steele, Executive VP and CFO, bought 2,064 shares of common stock in open-market purchases at a weighted average price of $9.16 per share. A footnote notes the total holdings also reflect 1,359 shares recently acquired through the company’s Employee Stock Purchase Plan.
InfuSystem Holdings furnished an investor presentation highlighting another year of record results and its long-term growth strategy. Net revenues reached $143.4 million in 2025, up from $134.9 million in 2024, marking seven consecutive years of record revenue. 2025 Adjusted EBITDA increased to $31.5 million, with Adjusted EBITDA margin improving to 21.9% and overall gross margin rising to 56.0%.
The presentation shows a balanced model between Patient Services and Device Solutions, with 2025 revenues of $86.5 million and $56.9 million, respectively. As of December 31, 2025, equity was $57.3 million, total long-term debt $19.6 million, net leverage 0.52x, and total available liquidity $58.2 million. Cash provided by operations over the trailing twelve months was $24.4 million. The company also discussed a renewed $20 million stock repurchase program, under which it had bought back $11 million of shares by year-end 2025.
InfuSystem Holdings, Inc. provides outpatient durable medical equipment services to hospitals, oncology practices, surgery centers and other alternate site providers through two platforms: Patient Services and Device Solutions. Patient Services focuses on clinic‑to‑home oncology and other therapies, while Device Solutions sells, rents and services infusion and wound-care equipment.
The Oncology Business is the lead service in Patient Services and generated about 87% of that segment’s 2025 net revenue, with roughly 43% from colorectal cancer treatments and 44% from non‑colorectal disease states. As of December 31, 2025, the rental fleet had a historical cost of $109.1 million and the company employed 473 people.
InfuSystem highlights competitive advantages from nearly 840 third‑party payer networks, a large pump fleet and seven U.S. and Canadian locations, but warns of extensive risks, including reimbursement changes, dependence on a major pump supplier, regulatory compliance, government shutdowns, cybersecurity threats, tax and macroeconomic uncertainty, and potential limits on using $5.8 million of U.S. federal net operating loss carryforwards.